Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
Status:
Withdrawn
Trial end date:
2017-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or
refractory patients diagnosed with active Kawasaki disease, administration of canakinumab
controls fever and acute phase reactants.